Gynecologic Cancer News

Members of American Society for Radiation Oncology elected three new officers to ASTRO’s board of directors.

Andre Nussenzweig, PhD, received the ninth annual Basser Global Prize.

In this episode, Carol L. Brown, MD, discusses her role as chief health equity officer at MSKCC, her thoughts on the future of structural inequities, strategies to diversify clinical trials, and more.

In 2010, results of the phase 2 BATTLE study demonstrated that choice of cancer therapy could be individualized based upon a patient’s tumor characteristics.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed results from the TOTEM trial presented at the ASCO Annual Meeting.

The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, spoke with Healio about findings from a study examining survival with longer vs. shorter duration of bevacizumab therapy in patients with advanced ovarian cancer.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed the “practice-changing” results from the OUTBACK trial.

The COVID-19 pandemic has underscored the importance of vaccination, both in terms of protecting individuals from infection and eradicating threats to public health.

During a communication experiment, brief videos of a pediatrician announcing to parents that their child is due for an HPV vaccine and easing their concerns reduced HPV vaccine hesitancy, data showed.